0:13:54 · Steven Baxter, Wells Fargo · 2027 outlook
What are the headwinds and tailwinds for 2027, and how much individual MA margin progress should we expect?
Management sees no new headwinds beyond the carried-over Stars headwind and several tailwinds (cost transformation, Medicaid and primary care maturation, improved pricing, fewer new members), and expects a material margin improvement without giving a number. — Humana management
0:15:47 · Justin Lake, Wolfe Research · Cost trends
How are cost trends running for 2026 and 2027, and what is driving the pressure in CenterWell Primary Care?
2026 trend is at the lower end of 7 to 8% with inpatient and Part D favorability, 2027 trend is priced at 8 to 9% with Part D up 14 to 15%, and the primary care pressure is in one geography that management says has been contained through contracting, benefit and network actions. — Celeste Mellet
0:19:27 · Anne Hines, Mizuho · 2027 enrollment
How much will MA membership grow in 2027 and were there surprises in the competitive annual enrollment period?
Product positioning is as expected and distribution partners are outperforming, but management will not size 2027 growth because it lacks retention data. — Jim Rechtin, Celeste Mellet
0:21:50 · Matthew Gilmore, KeyBanc · Primary care costs
Can you quantify the primary care cost pressure and will it be fully mitigated in 2027?
Management has not broken out the amount, says it is not meaningful to the enterprise, and expects to offset most of it through actions by CenterWell, Humana and other payers. — Humana management
0:22:23 · David Windley, Jefferies · Stars tailwind
How much of the margin path to the 3% target is Stars versus operations, and how will the Stars surplus be split?
The split will not be quantified until late 2027 because it depends on the gap to top quartile, membership size and mix, and operational capacity to invest, but management says the surplus is too large to invest in full. — Jim Rechtin, Celeste Mellet
0:27:59 · Jason Casarla, Guggenheim Securities · Capital deployment
How are you thinking about future acquisitions and restarting share repurchases as earnings and cash flow grow?
Capital goes first to funding insurance subsidiaries, then to Medicaid and CenterWell through organic growth or M&A, with dividend growth to follow as earnings recover and buybacks currently just offsetting dilution. — Jim Rechtin, Celeste Mellet
0:32:52 · AJ Rice, UBS · Stars strategy
Why manage to top-quartile Stars rather than the roughly 90% four-star level of the past, and will value-based care share grow beyond 30%?
Targeting top quartile is meant to impose discipline on benefits and costs while still aiming to do better, and Humana wants to partner with high-quality providers whether or not they take risk, without a material change in value-based share. — Jim Rechtin, Celeste Mellet
0:39:01 · Kevin Fishbeck, Bank of America · Earnings progression
Is the 2028 Stars surplus on top of the 2028 target, and how will earnings from Medicaid, CenterWell, Group MA and capital deployment phase in across 2027 and 2028?
The Stars surplus is on top of the 2028 target, and management says every line item of the investor day waterfall is ahead of plan, including Group MA margin improved by 500 basis points, with 2027 and 2028 both steeper than previously expected. — Jim Rechtin, Celeste Mellet
0:43:21 · Scott Fidel, Goldman Sachs · Reinsurance
How has the use of reinsurance in Medicare Advantage evolved and will it continue into 2027?
Reinsurance cut the capital put into subsidiaries from about 12% of premiums to just under 10%, it is cheaper than debt funding, and management expects little change over the next couple of years. — Celeste Mellet
0:46:19 · Andrew Mock, Barclays · Provider partners
How will Stars bonus revenue flow through to capitated provider partners on the way back up?
Humana shielded higher-quality providers from the headwind based on performance, so recovery up to the target partly reverses that support, while upside above the target is fully shared through the 30% offset. — Celeste Mellet
0:47:45 · George Hill, Deutsche Bank · 2027 pricing
How much of 2027 margin expansion comes from pricing versus cost control, given trend priced above what is currently running?
Management says trend is priced at 8 to 9% because of Part D, that the incremental 2027 progress is largely from pricing, and that the approach reflects operating discipline rather than conservatism. — Celeste Mellet, Jim Rechtin